Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Improved process conditions for increasing expression of MHC class II protein from a stable Drosophila S2 cell line.

Shen X, Dojcinovic D, Baldi L, Hacker DL, Luescher IF, Wurm FM.

Biotechnol Lett. 2018 Jan;40(1):85-92. doi: 10.1007/s10529-017-2440-0. Epub 2017 Oct 9.

PMID:
28993910
2.

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.

Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher I, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD.

Biochemistry. 2017 Aug 1;56(30):3945-3961. doi: 10.1021/acs.biochem.7b00385. Epub 2017 Jul 19.

PMID:
28671821
3.

In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Schmidt J, Guillaume P, Dojcinovic D, Karbach J, Coukos G, Luescher I.

J Biol Chem. 2017 Jul 14;292(28):11840-11849. doi: 10.1074/jbc.M117.789511. Epub 2017 May 23.

PMID:
28536262
4.

Current tools for predicting cancer-specific T cell immunity.

Gfeller D, Bassani-Sternberg M, Schmidt J, Luescher IF.

Oncoimmunology. 2016 Apr 25;5(7):e1177691. doi: 10.1080/2162402X.2016.1177691. eCollection 2016 Jul. Review.

5.

CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Leignadier J, Favre S, Luther SA, Luescher IF.

Oncoimmunology. 2015 Sep 11;5(3):e1086861. eCollection 2016 Mar.

6.

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.

7.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

8.

MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies.

Held G, Luescher IF, Neumann F, Papaioannou C, Schirrmann T, Sester M, Smola S, Pfreundschuh M.

J Immunol. 2015 Nov 1;195(9):4210-7. doi: 10.4049/jimmunol.1402902. Epub 2015 Sep 28.

9.

Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.

Hebeisen M, Schmidt J, Guillaume P, Baumgaertner P, Speiser DE, Luescher I, Rufer N.

Cancer Res. 2015 May 15;75(10):1983-91. doi: 10.1158/0008-5472.CAN-14-3516. Epub 2015 Mar 25.

10.

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.

11.

Duality of the murine CD8 compartment.

Genolet R, Leignadier J, Østerås M, Farinelli L, Stevenson BJ, Luescher IF.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):E1007-15. doi: 10.1073/pnas.1317847111. Epub 2014 Mar 4.

12.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

13.

Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.

Schmidt J, Dojcinovic D, Guillaume P, Luescher I.

Front Immunol. 2013 Jul 30;4:218. doi: 10.3389/fimmu.2013.00218. eCollection 2013.

14.

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion.

Utzschneider DT, Legat A, Fuertes Marraco SA, Carrié L, Luescher I, Speiser DE, Zehn D.

Nat Immunol. 2013 Jun;14(6):603-10. doi: 10.1038/ni.2606. Epub 2013 May 5.

PMID:
23644506
15.

Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.

Muraoka D, Nishikawa H, Noguchi T, Wang L, Harada N, Sato E, Luescher I, Nakayama E, Kato T, Shiku H.

Vaccine. 2013 Apr 19;31(17):2110-8. doi: 10.1016/j.vaccine.2013.02.056. Epub 2013 Mar 13.

PMID:
23499606
16.

CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire.

Verhagen J, Genolet R, Britton GJ, Stevenson BJ, Sabatos-Peyton CA, Dyson J, Luescher IF, Wraith DC.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):E221-30. doi: 10.1073/pnas.1208573110. Epub 2012 Dec 24.

17.

Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination.

Genolet R, Stevenson BJ, Farinelli L, Osterås M, Luescher IF.

EMBO J. 2012 Nov 5;31(21):4247-8. doi: 10.1038/emboj.2012.277. No abstract available.

18.

An optimized method for establishing high purity murine CD8+ T cell cultures.

Zanker D, Xiao K, Oveissi S, Guillaume P, Luescher IF, Chen W.

J Immunol Methods. 2013 Jan 31;387(1-2):173-80. doi: 10.1016/j.jim.2012.10.012. Epub 2012 Oct 22.

PMID:
23098837
19.

Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering.

Molnár E, Swamy M, Holzer M, Beck-García K, Worch R, Thiele C, Guigas G, Boye K, Luescher IF, Schwille P, Schubert R, Schamel WW.

J Biol Chem. 2012 Dec 14;287(51):42664-74. doi: 10.1074/jbc.M112.386045. Epub 2012 Oct 22.

20.

The T-cell receptor is not hardwired to engage MHC ligands.

Holland SJ, Bartok I, Attaf M, Genolet R, Luescher IF, Kotsiou E, Richard A, Wang E, White M, Coe DJ, Chai JG, Ferreira C, Dyson J.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3111-8. doi: 10.1073/pnas.1210882109. Epub 2012 Oct 17.

21.

A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM, Dimopoulos N, Guillaume P, Knights AJ, Lowen T, Robson NC, Russell SE, Scotet E, Davis ID, Maraskovsky E, Cebon J, Luescher IF, Chen W.

PLoS One. 2012;7(9):e44707. doi: 10.1371/journal.pone.0044707. Epub 2012 Sep 6.

22.

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Poli C, Raffin C, Dojcinovic D, Luescher I, Ayyoub M, Valmori D.

Haematologica. 2013 Feb;98(2):316-22. doi: 10.3324/haematol.2012.071712. Epub 2012 Aug 8.

23.

KAP1 regulates gene networks controlling T-cell development and responsiveness.

Santoni de Sio FR, Barde I, Offner S, Kapopoulou A, Corsinotti A, Bojkowska K, Genolet R, Thomas JH, Luescher IF, Pinschewer D, Harris N, Trono D.

FASEB J. 2012 Nov;26(11):4561-75. doi: 10.1096/fj.12-206177. Epub 2012 Aug 7.

24.

TSLP promotes influenza-specific CD8+ T-cell responses by augmenting local inflammatory dendritic cell function.

Yadava K, Sichelstiel A, Luescher IF, Nicod LP, Harris NL, Marsland BJ.

Mucosal Immunol. 2013 Jan;6(1):83-92. doi: 10.1038/mi.2012.50. Epub 2012 Jul 18.

25.

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.

Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E.

Int J Cancer. 2013 Jan 15;132(2):345-54. doi: 10.1002/ijc.27682. Epub 2012 Jul 11.

26.

Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, Michielin O.

J Biol Chem. 2012 Jun 29;287(27):23068-78. doi: 10.1074/jbc.M112.357673. Epub 2012 May 1.

27.

Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination.

Genolet R, Stevenson BJ, Farinelli L, Osterås M, Luescher IF.

EMBO J. 2012 Apr 4;31(7):1666-78. doi: 10.1038/emboj.2012.48. Epub 2012 Feb 28.

28.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM.

Cancer Res. 2012 Feb 15;72(4):887-96. doi: 10.1158/0008-5472.CAN-11-2637. Epub 2011 Dec 28.

29.

Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.

Lövgren T, Baumgaertner P, Wieckowski S, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE.

Cancer Immunol Immunother. 2012 Jun;61(6):817-26. doi: 10.1007/s00262-011-1140-1. Epub 2011 Nov 12.

PMID:
22080404
30.

Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.

Schmidt J, Guillaume P, Irving M, Baumgaertner P, Speiser D, Luescher IF.

J Biol Chem. 2011 Dec 2;286(48):41723-35. doi: 10.1074/jbc.M111.283127. Epub 2011 Oct 11.

31.

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Redjimi N, Duperrier-Amouriaux K, Raimbaud I, Luescher I, Dojcinovic D, Classe JM, Berton-Rigaud D, Frenel JS, Bourbouloux E, Valmori D, Ayyoub M.

PLoS One. 2011;6(7):e22845. doi: 10.1371/journal.pone.0022845. Epub 2011 Jul 29.

32.

Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.

Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE.

Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.

33.

Basal and antigen-induced exposure of the proline-rich sequence in CD3ε.

de la Cruz J, Kruger T, Parks CA, Silge RL, van Oers NS, Luescher IF, Schrum AG, Gil D.

J Immunol. 2011 Feb 15;186(4):2282-90. doi: 10.4049/jimmunol.1003225. Epub 2011 Jan 12.

34.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM.

J Exp Med. 2010 Sep 27;207(10):2175-86. doi: 10.1084/jem.20100637. Epub 2010 Sep 6.

35.

Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.

Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I, Old LJ, Shiku H, Nishikawa H.

J Immunol. 2010 Sep 15;185(6):3768-76. doi: 10.4049/jimmunol.0903649. Epub 2010 Aug 23.

36.

Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.

Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.

J Immunol. 2010 Sep 15;185(6):3445-55. doi: 10.4049/jimmunol.1001397. Epub 2010 Aug 23.

37.

Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.

Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D.

Clin Cancer Res. 2010 Sep 15;16(18):4607-15. doi: 10.1158/1078-0432.CCR-10-1485. Epub 2010 Jul 29.

38.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7437-42. doi: 10.1073/pnas.1001322107. Epub 2010 Apr 5.

39.

Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.

Guillaume P, Baumgaertner P, Neff L, Rufer N, Wettstein P, Speiser DE, Luescher IF.

Int J Cancer. 2010 Aug 15;127(4):910-23. doi: 10.1002/ijc.25099.

40.

Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.

Cancer Res. 2009 Oct 15;69(20):8085-93. doi: 10.1158/0008-5472.CAN-09-2226. Epub 2009 Oct 6.

41.
42.

Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

Neumann F, Sturm C, Hülsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G.

Immunol Lett. 2009 Aug 15;125(2):86-92. doi: 10.1016/j.imlet.2009.06.002. Epub 2009 Jun 12.

PMID:
19524620
43.

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.

44.

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J.

Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24.

45.
46.

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.

Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.

Cancer Res. 2009 Feb 1;69(3):1046-54. doi: 10.1158/0008-5472.CAN-08-2926. Epub 2009 Jan 27. Erratum in: Cancer Res. 2009 May 15;69(10):4553.

47.

HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.

Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.

Clin Cancer Res. 2009 Jan 1;15(1):299-306. doi: 10.1158/1078-0432.CCR-08-1747.

48.

An essential role for the stalk region of CD8 beta in the coreceptor function of CD8.

Rettig L, McNeill L, Sarner N, Guillaume P, Luescher I, Tolaini M, Kioussis D, Zamoyska R.

J Immunol. 2009 Jan 1;182(1):121-9.

49.

CD8beta knockout mice mount normal anti-viral CD8+ T cell responses--but why?

Angelov GS, Guillaume P, Luescher IF.

Int Immunol. 2009 Feb;21(2):123-35. doi: 10.1093/intimm/dxn130. Epub 2008 Dec 15.

PMID:
19088062
50.

Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells.

Dimopoulos N, Jackson HM, Ebert L, Guillaume P, Luescher IF, Ritter G, Chen W.

J Immunol Methods. 2009 Jan 1;340(1):90-4. doi: 10.1016/j.jim.2008.09.023. Epub 2008 Oct 26.

PMID:
18957296

Supplemental Content

Loading ...
Support Center